Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioversys Completes BV100 Phase 2 for Ventilator-Associated Pneumonia
Details : BV100 a novel formulation of rifabutin, being investigated in adults with ventilator associated bacterial pneumonia suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : GIBF2
Deal Size : $6.0 million
Deal Type : Financing
Bioversys Secures Investment For BV100 Clinical Program in China
Details : The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 11, 2024
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : GIBF2
Deal Size : $6.0 million
Deal Type : Financing
Lead Product(s) : BV500
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : CF AMR Syndicate
Deal Size : $0.6 million
Deal Type : Funding
BioVersys gets Non-Dilutive Funds from CF AMR Syndicate Collaborative Discovery Programme
Details : The proceeds will support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).
Product Name : BV500
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 04, 2024
Lead Product(s) : BV500
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : CF AMR Syndicate
Deal Size : $0.6 million
Deal Type : Funding
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : GSK
Deal Size : $49.5 million
Deal Type : Series C Financing
BioVersys Expands Collaboration with GSK and Extends Series C Round By CHF 12.3M
Details : Proceeds will enable the clinical development of BioVersys’ portfolio, including BV100 (rifabutin), a breakthrough antibiotic targeting Acinetobacter baumannii, a highly resistant bacterial pathogen.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : GSK
Deal Size : $49.5 million
Deal Type : Series C Financing
Lead Product(s) : Alpibectir,Ethionamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
BioVersys Expands Collaboration with GSK, Extending Series C Round by CHF 12.3 Million
Details : The collaboration with the GSK to accelerate the clinical development of BVL-GSK098 (alpibectir) for the treatment of tuberculosis.
Product Name : BVL-GSK098
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Alpibectir,Ethionamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BV200
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Financing
AMR Action Fund Announces Investment in BioVersys AG
Details : The financing aims to advance antimicrobial drugs including BV200, which is being developed for patients who have severe hospital-acquired Staphylococcus aureus infections.
Product Name : BV200
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : BV200
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : BV300
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $15.3 million
Deal Type : Funding
BioVersys Receives a Second CARB-X Award of up to US$ 15.34 Million for BV300
Details : The funding aims to advance the development of BV300, chemical class of broad-spectrum antibiotics known as pyrrolocytosines. It is being evaluated for treating Enterococcus faecium Infections.
Product Name : BV300
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : BV300
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $15.3 million
Deal Type : Funding
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Financing
BioVersys Receives €20 Million in EU Financing to Support Development of New Antibiotics
Details : The financing aims to advance the clinical development of Bioversys pipeline including BV100, which is being evaluated for the treatment of Carbapenem-resistant Acinetobacter baumannii Infection.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 04, 2021
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Alpibectir,Ethionamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : EDCTP
Deal Size : $2.8 million
Deal Type : Funding
BioVersys, TASK and GSK Receive 2.7 Million Euro from EDCTP for Phase 2a Clinical Trial
Details : The funding aims to advance the development of BVL-GSK098 (alpibectir) in combination withethionamide for treating Drug-Susceptible Pulmonary Tuberculosis in adult.
Product Name : BVL-GSK098
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 25, 2021
Lead Product(s) : Alpibectir,Ethionamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : EDCTP
Deal Size : $2.8 million
Deal Type : Funding
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioVersys Announces First Subjects Dosed in Ph 1 Clinical Trial of BV100
Details : BioVersys has developed a proprietary human IV formulation of BV100 for the CRAB hospital market and elucidated the unique mode of action that accounts for its tremendous potency and coverage of clinical CRAB isolates.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 18, 2020
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable